Vizsgálati helyszín
Azienda Ospedaliera Papardo
Messina, 98158, OlaszországMég nincs intézményhez kötve
- 18futó vizsgálat
- 8lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 26 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis16 vizsgálat
- 2. fázis7 vizsgálat
- 1/2. fázis1 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz12 vizsgálat
- Lezárult8 vizsgálat
- Még nem toboroz3 vizsgálat
- Toboroz3 vizsgálat
- Fő szponzor
- AstraZeneca3 vizsgálat
- Gruppo Italiano Malattie EMatologiche dell'Adulto3 vizsgálat
- AstraZeneca AB2 vizsgálat
- European Myeloma Network B.V.2 vizsgálat
- Fondazione Italiana Linfomi - ETS2 vizsgálat
- és még 13
Futó vizsgálatok
Toboroz
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
NCT07430956· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
2023-505775-70-00· 2. fázis· European Myeloma Network B.V.· Forrás
Fut, nem toboroz
Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL
NCT05478512· 2. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Fut, nem toboroz
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108· 1/2. fázis· Stemline Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348· 3. fázis· European Myeloma Network B.V.· Forrás
Fut, nem toboroz
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
NCT05058404· 3. fázis· Fondazione Italiana Linfomi - ETS· Forrás
Fut, nem toboroz
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
NCT04722848· 3. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Fut, nem toboroz
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the
Metastatic Setting
2024-516653-44-00· 3. fázis· AstraZeneca AB· Forrás
Toboroz
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
NCT04168502· 3. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Toboroz
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations
NCT04811001· 2. fázis· Fondazione Ricerca Traslazionale· Forrás
Fut, nem toboroz
Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with Activated-B-Cell (ABC)-DLBCL at intermediate-high and high risk (IPI ≥2)
NCT03731234· 2. fázis· Fondazione Italiana Linfomi Ets· Forrás
Fut, nem toboroz
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
NCT04096066· 3. fázis· Fondazione EMN Italy Onlus· Forrás
Még nem toboroz
A randomized phase II study of Pembrolizumab (MK-3475) as maintainance
therapy in patients with unresectable stage III non-small cell lung cancer treated with
definitive chemo-radiotherapy (MP-LALC- Maintainance Pembrolizumab in Locally
Advanced Lung Cancer).
NCT03379441· 2. fázis· Universita' Degli Studi Di Torino· Forrás
Fut, nem toboroz
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients
NCT02390869· 3. fázis· Fondazione Italiana Linfomi - ETS· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy
2023-506696-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Fut, nem toboroz
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
NCT04765059· 3. fázis· AstraZeneca· Forrás
Lezárult
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
NCT04746924· 3. fázis· Beigene Ltd.· Forrás
Lezárult
Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal cancer who have failed in previous therapies.
2024-513296-41-00· 2. fázis· Fondazione GONO G.I.· Forrás
Fut, nem toboroz
A trial to learn how camizestrant (AZD9833) works compared to fulvestrant and how safe it is in women with advanced breast cancer who have gone through menopause.
NCT04214288· 2. fázis· AstraZeneca AB· Forrás
Lezárult
The European Robotic Spinal Instrumentation (EUROSPIN) Study
NCT03398915· Marc Schröder· Forrás
Lezárult
Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing a drug called Nilotinib versus another called Imatinib with switch to Nilotinib in absence of optimal response.
NCT02602314· 4. fázis· Fondazione Gimema Franco Mandelli Onlus· Forrás
Lezárult
Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
NCT01208766· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Hibát jelzek